Co-existence: 25 metres sufficient


Wageningen – A Dutch analysis has concluded that the country’s forseen GMO regulations for coexistance are efficient. A preliminary analysis of the two-year program carried out by the University of Wageningen and the Institute for Food Safety has shown that a 25-metre isolation distance is sufficient to avoid labeling obligations for farmers with conventional or organic maize in the neighbourhood of GM maize cultivations. The researchers found that the distance led to an average content of 0.01% to 0.3% of insect-resistant Bt-maize (MON810) in the non-GM crops. At a distance of 250 metres, the average outcrossing rate lays between 0% and 0.003%. Accordingly, all measured rates remained far below the EU labeling threshold of 0.9%.Another part of the Dutch coexistance agreement was a risk analysis with an evaluation of potential economical damages to conventional or organic farmers caused by the cultivation of GM crops in the Netherlands. This study was conducted by the Institute for Risk Management in Agriculture at the University of Wageningen and comprises damage scenarios for maize, potatoes and sugar beet. According to the scientists, the analysis reveals that the value for the average direct economic damage as a consequence of cross breeding is almost zero.



Brussels – Promethera Biosciences has completed a Series B financing round, generating proceeds of €23.6m. The Belgian cell therapy company secured a capital increase of €17m from its new investors, among them the venture arms...



Leuven – Biopharmaceutical company ThromboGenics has entered into an agreement with Alcon Inc., a division of Novartis for the commercialisation of its product ocriplasmin in all markets outside the U.S. ThromboGenics said it...



Amsterdam Molecular Therapeutics has announced a financial manoeuvre aimed at getting the biotech out of a hopeless situation. The assets and – more importantly – the liabilities of the drug developer will be acquired by a newly...



Amsterdam - Amsterdam Molecular Therapeutics has announced a financial manoeuvre which is aimed to get the biotech out of a dead end. The assets and – more importantly – the liabilities of the drug developer will be acquired by...



Glasgow/Leuven - With a little help from the EU, two biotech companies are banding together to develop the first stem cell therapy against rheumatoid arthritis. UK-based Sistemic will work with TiGenix to develop the Belgian's...



Amsterdam – Two elephants in the biofuels business join forces. Dutch food and chemicals group Royal DSM and POET, LLC, a US-based ethanol producer, announced a plan to build a commercial cellulosic ethanol plant. POET–DSM...



Heerlen - Royal DSM N.V will be the industrial partner to the Panoptes consortium, which aims to develop novel drug delivery technology for the posterior eye segment. The four year project is supported by EUR4m in funding from...



Leiden - Dutch Pharming Group NV has taken a further step to secure sound financing even beyond the recent milestone payments. The drug developer announced that it has entered into a financing of approximately €8.4 million by...



Ghent – Just days after US pharmaceuticals giant Pfizer pulled out of a rheumatoid arthritis pact with Ablynx NV, the Belgian biopharmaceutical company expanded its relationship with Merck Serono. Ablynx has now entered into a...

Displaying results 1 to 10 out of 304

1-10 Next >

© 2007-2014 BIOCOM

Product of the week



All Events

Current issue

All issues